Patents by Inventor Eric Marsault

Eric Marsault has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10258602
    Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: April 16, 2019
    Assignee: Ocera Therapeutics, Inc.
    Inventors: Hamid Hoveyda, Graeme Fraser, Kamel Benakli, Eric Marsault, Mark L. Peterson
  • Patent number: 10208308
    Abstract: The present invention provides matriptase inhibitors and compositions for treating and preventing orthomyxovirus infections such as flue infections. The present invention also provides novel compounds, compositions, methods of use, uses and kits thereof for inhibiting matriptase. Such compounds are useful for treating and prevention orthomyxovirus infections, such as flu infections, and for inhibiting tumor growth, progression and/or metastasis.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: February 19, 2019
    Assignee: Socpra Sciences Sante Et Humaines S.E.C.
    Inventors: Martin Richter, Richard Leduc, Eloic Colombo, Eric Marsault
  • Publication number: 20190008875
    Abstract: The present invention provides bacterial ATP synthase inhibitors such as a compound of formula (I): There are provided compositions and kits using such compounds and inhibitors.
    Type: Application
    Filed: September 20, 2018
    Publication date: January 10, 2019
    Inventors: ÉRIC MARSAULT, FRANÇOIS MALOUIN, FÉLIX CHAGNON, ISABELLE GUAY, SIMON BOULANGER
  • Publication number: 20180362582
    Abstract: The present invention provides a macrocyclic compound of formula (I) compositions and kits comprising this compound and their use for preventing or treating pain, or inducing hypothermia or hypotension.
    Type: Application
    Filed: June 18, 2018
    Publication date: December 20, 2018
    Inventors: Éric Marsault, Marc Sousbie, Richard Leduc, Philippe Sarret, Jean-Michel Longpré, Élie Besserer-Offroy, Rebecca Brouillette, Michael Desgagné
  • Patent number: 10137137
    Abstract: The present invention provides bacterial ATP synthase inhibitors such as a compound of formula (I): (Formula (I)) (A) in combination with an aminoglycoside antibiotic for preventing or treating a bacterial infection in a subject; or (B) (a) for preventing or treating an infection caused by an electron transport-deficient bacteria in a subject; or (b) for the disinfection, sterilization and/or antisepsis of an object contaminated with an electron transport-deficient bacteria. There are provided compositions and kits using such compounds and inhibitors.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: November 27, 2018
    Assignee: Socpra Sciences et Genie S.E.C.
    Inventors: Éric Marsault, François Malouin, Félix Chagnon, Isabelle Guay, Simon Boulanger
  • Publication number: 20180228768
    Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
    Type: Application
    Filed: March 28, 2018
    Publication date: August 16, 2018
    Inventors: Hamid Hoveyda, Graeme Fraser, Kamel Benakli, Eric Marsault, Mark L. Peterson
  • Patent number: 10040751
    Abstract: The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as described in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: August 7, 2018
    Assignee: Ocera Therapeutics, Inc.
    Inventors: Eric Marsault, Kamel Benakli, Hamid Hoveyda, Mark L. Peterson, Sylvie Beaubien, Luc Ouellet, Carl St-Louis, Sophie Beauchemin
  • Patent number: 9993491
    Abstract: The present invention includes novel compounds and pharmaceutically acceptable formulations of said compounds which exhibit antibiotic activity against microorganisms bearing a guanine riboswitch that controls the expression of the guaA gene, including organisms which are resistant to certain antibiotic families, and which are useful as antibacterial agents for treatment or prophylaxis of bacterial infections in animals or in humans, in particular but not limited to infections of the mammary gland, or their use as antiseptics, agents for sterilization or disinfection.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: June 12, 2018
    Assignee: SOCPRA—SCIENCES ET GÉNIE S.E.C.
    Inventors: Jerome Mulhbacher, Daniel Lafontaine, Francois Malouin, Marianne Allard, Eric Marsault
  • Patent number: 9949949
    Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone sceretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: April 24, 2018
    Assignee: Ocera Therapeutics, Inc.
    Inventors: Hamid Hoveyda, Graeme Fraser, Kamel Benakli, Eric Marsault, Mark L. Peterson
  • Publication number: 20170320908
    Abstract: The present invention relates to cyclic amino acid molecules and methods of preparing the same, and in particular the macrocyclization of amino acids or linear peptides bound to a solid support.
    Type: Application
    Filed: November 17, 2015
    Publication date: November 9, 2017
    Inventors: Jennifer L. Hickey, John Mancuso, Eric Marsault, Andrew L. Roughton, Adam P. Treder, Marie-Claude J. Trembley, Andrei K. Yudin, Serge Zaretsky
  • Publication number: 20170314023
    Abstract: The present invention provides matriptase inhibitors and compositions for treating and preventing orthomyxovirus infections such as flue infections. The present invention also provides novel compounds, compositions, methods of use, uses and kits thereof for inhibiting matriptase. Such compounds are useful for treating and prevention orthomyxovirus infections, such as flu infections, and for inhibiting tumor growth, progression and/or metastasis.
    Type: Application
    Filed: July 12, 2017
    Publication date: November 2, 2017
    Inventors: Martin Richter, Richard Leduc, Eloic Colombo, Eric Marsault
  • Patent number: 9752149
    Abstract: The present invention provides matriptase inhibitors and compositions for treating and preventing orthomyxovirus infections such as flu infections. The present invention also provides novel compounds, compositions, methods of use, uses and kits thereof for inhibiting matriptase. Such compounds are useful for treating and preventing orthomyxovirus infections, such as flu infections, and for inhibiting tumor growth, progression and/or metastasis.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: September 5, 2017
    Assignee: SOCPRA SCIENCES SANTE ET HUMAINES S.E.C.
    Inventors: Martin Richter, Richard Leduc, Eloic Colombo, Eric Marsault
  • Publication number: 20170042858
    Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone sceretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
    Type: Application
    Filed: June 9, 2016
    Publication date: February 16, 2017
    Inventors: Hamid Hoveyda, Graeme Fraser, Kamel Benakli, Eric Marsault, Mark L. Peterson
  • Patent number: 9493505
    Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: November 15, 2016
    Assignee: OCERA THERAPEUTICS, INC.
    Inventors: Eric Marsault, Carl St-Louis
  • Publication number: 20160317556
    Abstract: The present invention provides bacterial ATP synthase inhibitors such as a compound of formula (I): (Formula (I)) (A) in combination with an aminoglycoside antibiotic for preventing or treating a bacterial infection in a subject; or (B) (a) for preventing or treating an infection caused by an electron transport-deficient bacteria in a subject; or (b) for the disinfection, sterilization and/or antisepsis of an object contaminated with an electron transport-deficient bacteria. There are provided compositions and kits using such compounds and inhibitors.
    Type: Application
    Filed: December 23, 2014
    Publication date: November 3, 2016
    Inventors: ÉRIC MARSAULT, FRANÇOIS MALOUIN, FÉLIX CHAGNON, ISABELLE GUAY, SIMON BOULANGER
  • Patent number: 9457033
    Abstract: The present invention includes novel compounds based on the tomatidine skeleton as well as composition comprising these compounds alone and in combination with known compounds, which exhibit antimicrobial activity against extracellular or intracellular electron transport-deficient microbes and/or increase the antimicrobial activity of aminoglycoside antibiotics against their targets, and which are useful as antibacterial agents for treatment or prophylaxis of monomicrobiotic or polymicrobic bacterial infections or for the reduction of antibiotic resistance development in animals or in humans, or for use as antiseptics or agents for sterilization or disinfection.
    Type: Grant
    Filed: February 15, 2012
    Date of Patent: October 4, 2016
    Assignee: SOCPRA SCIENCES ET GENIE, S.E.C.
    Inventors: François Malouin, Gabriel Mitchell, Kamal Bouarab, Eric Marsault, Felix Chagnon, Simon Boulanger, Isabelle Guay
  • Publication number: 20160221927
    Abstract: The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as described in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.
    Type: Application
    Filed: October 1, 2015
    Publication date: August 4, 2016
    Inventors: Eric Marsault, Kamel Benakli, Hamid Hoveyda, Mark L. Peterson, Sylvie Beaubien, Luc Oullet, Carl St-Louis, Sophie Beauchemin
  • Patent number: 9371297
    Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
    Type: Grant
    Filed: February 8, 2008
    Date of Patent: June 21, 2016
    Assignee: Ocera Therapeutics, Inc.
    Inventors: Hamid Hoveyda, Graeme L. Fraser, Kamel Benakli, Sophie Beauchemin, Martin Brassard, Eric Marsault, Luc Oullet, Mark L. Peterson, Zhigang Wang
  • Patent number: 9365853
    Abstract: The present invention provides matriptase inhibitors and compositions for treating and preventing orthomyxovirus infections such as flu infections. The present invention also provides novel compounds, compositions, methods of use, uses and kits thereof for inhibiting matriptase. Such compounds are useful for treating and preventing orthomyxovirus infections, such as flu infections, and for inhibiting tumor growth, progression and/or metastasis.
    Type: Grant
    Filed: May 28, 2012
    Date of Patent: June 14, 2016
    Inventors: Martin Richter, Richard Leduc, Eloic Colombo, Eric Marsault
  • Publication number: 20160097052
    Abstract: The present invention provides matriptase inhibitors and compositions for treating and preventing orthomyxovirus infections such as flu infections. The present invention also provides novel compounds, compositions, methods of use, uses and kits thereof for inhibiting matriptase. Such compounds are useful for treating and preventing orthomyxovirus infections, such as flu infections, and for inhibiting tumor growth, progression and/or metastasis.
    Type: Application
    Filed: November 17, 2015
    Publication date: April 7, 2016
    Inventors: Martin Richter, Richard Leduc, Eloic Colombo, Eric Marsault